TAM
AKBA icon

Tocqueville Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Tocqueville Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21,300
Closed -$174K – 773
2019
Q1 		$174K Sell
21,300
-5,000
-19% -$34.3K ﹤0.01% 743
2018
Q4 		$145K Sell
26,300
-11,500
-30% -$90K ﹤0.01% 720
2018
Q3 		$334K Buy
+37,800
New +$338K ﹤0.01% 670
2015
Q4 		– Sell
-60,000
Closed -$580K – 908
2015
Q3 		$580K Buy
+60,000
New +$551K 0.01% 666

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tocqueville Asset Management's AKBA Position: Q2 2019 in Review

Tocqueville Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 21,300 shares — an estimated $174K sold.

Tocqueville Asset Management first reported a position in AKBA in Q3 2015 and held it in 4 quarters. The position peaked at $580K in Q3 2015. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Tocqueville Asset Management reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tocqueville Asset Management sold 21,300 Akebia Therapeutics shares in Q2 2019, an estimated $174K.
  • Tocqueville Asset Management first reported a position in Akebia Therapeutics in Q3 2015 and held it in 4 quarters.
  • Tocqueville Asset Management's Akebia Therapeutics position peaked at $580K in Q3 2015.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Tocqueville Asset Management's 13F filing for Q2 2019, filed 31 Jul 2019.